

ROCKWELL MEDICAL, INC.  
Form 8-K  
September 04, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

---

Date of Report

(Date of earliest

event reported): **September 4, 2018**

**ROCKWELL MEDICAL, INC.**

(Exact name of registrant as specified in its charter)

**Michigan**  
(State or other  
jurisdiction of  
incorporation)

**000-23661**  
(Commission File  
Number)

**38-3317208**  
(IRS Employer  
Identification No.)

**30142 Wixom Road, Wixom, Michigan 48393**

Edgar Filing: ROCKWELL MEDICAL, INC. - Form 8-K

(Address of principal executive offices, including zip code)

**(248) 960-9009**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



**Item 5.02**                      **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

Effective September 4, 2018, Stuart Paul commenced employment with Rockwell Medical, Inc. (the Company) as the Company's President and Chief Executive Officer. Effective upon Mr. Paul's commencement, the Company's Board of Directors (the Board) appointed Mr. Paul to serve as the Company's principal executive officer and principal financial officer.

Mr. Paul succeeds Benjamin Wolin who served as the Company's interim principal executive officer since August 10, 2018. In connection with the replacement of Mr. Wolin as the Company's interim principal executive officer, the Board reappointed Mr. Wolin to the Board's Compensation Committee and Governance and Nominating Committee (as an ex-officio member).

The additional biographical and other information concerning Mr. Paul as required by Item 5.02(c) of Form 8-K was included in the Company's Current Report on Form 8-K filed on August 8, 2018 and is incorporated by reference herein.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ROCKWELL MEDICAL, INC.**

Date: September 4, 2018

By:

/s/ Stuart Paul  
Stuart Paul  
President and Chief Executive Officer